Metformin HCl is one of the most effective and widely used therapeutics for treatment of type 2 diabetes. It selectively lowers the hepatic gluconeogenesis without rising insulin production, causing weight gain or hypoglycemia. [1]
AMPK (5'AMP-activated protein kinase) acts as a metabolic master switch regulating several intracellular systems including the cellular uptake of glucose, the β-oxidation of fatty acids and the biogenesis of GLUT4 (glucose transporter 4) and mitochondria.
In hepatocytes, AMPK was activated by metformin, followed by decreased ACC (acetyl-CoA carboxylase) activity, induction of fatty acid oxidization and suppression of lipogenic enzyme expression.[2] Metformin also inhibited mGPD (mitochondrial lycerophosphate dehydrogenase),a redox shuttle enzyme, leading to an altered hepatocellular redox state, decreased conversion of lactate and reduced hepatic gluconeogenesis. [1]
In rats treated with metformin, hepatic expression of SEREP-1 mRNAs/protein and activity of ACC were reduced. [2] In metformin treated mice, LKB1 in liver was essential for the ability of metformin to reduce blood glucose [3]. In ASO (Antisense oligonucleotide) knockdown of hepatic mGOD in rats, the phenotype was similar to chronic metformin treatment. It abolished mefromin-induced cytosolic redox state, reduction in plasma glucose concentration and EGP inhibition. [1]
盐酸二甲双胍是治疗2型糖尿病最有效、应用最广泛的药物之一。它选择性地降低肝脏糖异生，而不会增加胰岛素产量，导致体重增加或低血糖。[1]
AMPK（5’AMP活化的蛋白激酶）作为代谢主开关，调节几个细胞内系统，包括葡萄糖的细胞摄取、脂肪酸的β-氧化以及GLUT4（葡萄糖转运蛋白4）和线粒体的生物发生。
在肝细胞中，AMPK被二甲双胍激活，随后ACC（乙酰辅酶A羧化酶）活性降低，诱导脂肪酸氧化并抑制脂肪生成酶的表达。[2] 二甲双胍还抑制mGPD（线粒体甘油磷酸脱氢酶），这是一种氧化还原穿梭酶，导致肝细胞氧化还原状态改变，乳酸转化率降低，肝糖异生减少。[1]
在用二甲双胍治疗的大鼠中，肝脏SEREP-1 mRNA/蛋白的表达和ACC的活性降低。[2] 在二甲双胍治疗的小鼠中，肝脏中的LKB1对二甲双胍降低血糖的能力至关重要[3]。在大鼠肝mGOD的ASO（反义寡核苷酸）敲除中，表型与慢性二甲双胍治疗相似。它消除了mefromin诱导的胞质氧化还原状态、血浆葡萄糖浓度降低和EGP抑制。[1]
参考文献:
1. Madiraju AK, Erion DM, Rahimi Y et al.? Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase.? Nature. 2014 Jun 26;510(7506):542-6.
2. Zhou G, Myers R, Li Y et al.? Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001 Oct;108(8):1167-74.
3. Shaw RJ, Lamia KA, Vasquez D et al.? The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005 Dec 9;310(5754):1642-6.
| Kinase experiment [1]: | |
|
AMPK assay |
For the AMPK assay, cells were seeded in six-well plates at 1.5 × 106 cells/well in DMEM containing 100 U/ml penicillin, 100 μg/ml streptomycin, 10% FBS, 100 nM insulin, 100 nM dexamethasone, and 5 μg/ml transferrin for 4 hours. Cells were then cultured in serum-free DMEM for 16 hours followed by treatment for 1 hour or 7 hours with control medium, 5-amino-imidazole carboxamide riboside (AICAR), or metformin at concentrations indicated. For a 39-hour treatment, cells for both control and metformin (10 or 20 μM) groups were cultured in DMEM plus 5% FBS and 100 nM insulin, and the fresh control and metformin-containing medium were replaced every 12 hours (last medium change was 3 hours before harvest). After treatment, the cells were directly lysed in digitonin-containing and phosphatase inhibitor–containing buffer A , followed by precipitation with ammonium sulfate at 35% saturation. AMPK activity was determined by measurement of phosphorylation of a synthetic peptide substrate, SAMS (HMRSAMSGLHLVKRR). |
| Cell experiment [1]: | |
|
Cell lines |
Rat primary hepatocytes |
|
Preparation method |
The solubility of this compound in DMSO is limited. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
10, 20, 500 μM, 2 mM; 39h; |
|
Applications |
Metformin activated AMPK in primary hepatocytes. Moreover, Metformin (2 mM, 3 hours) stimulated AMPK activity in skeletal muscle in association with induction of glucose uptake. Metformin (500 μM) reduced hepatic SREBP-1 expression in rat hepatocytes. |
| Animal experiment: | |
|
Animal models |
Male C57BL/6 mice model; |
|
Dosage form |
200 mg/kg, oral gavage, twice daily for 5 days; or 250 mg/kg, intraperitoneal injection, for 3 days |
|
Applications |
Acetyl-CoA carboxylase (ACC) activity were reduced in metformin-treated rats [1]. Moreover, metformin required LKB1 in the liver to lower blood glucose levels [2]. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
参考文献: 1. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J. and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 108, 1167-1174 2. Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S. H., Bardeesy, N., Depinho, R. A., Montminy, M. and Cantley, L. C. (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 310, 1642-1646 |
|
动态评分
0.0